Matinas BioPharma Holdings, Inc. 6LJ.F Stock
Matinas BioPharma Holdings, Inc. Price Chart
Matinas BioPharma Holdings, Inc. 6LJ.F Financial and Trading Overview
Matinas BioPharma Holdings, Inc. stock price | 0.17 EUR |
Previous Close | 0.18 EUR |
Open | 0.19 EUR |
Bid | 0.19 EUR x 0 |
Ask | 0.24 EUR x 0 |
Day's Range | 0.19 - 0.23 EUR |
52 Week Range | 0.1 - 0.68 EUR |
Volume | 10K EUR |
Avg. Volume | 2.45K EUR |
Market Cap | 50.84M EUR |
Beta (5Y Monthly) | 1.947 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.38 EUR |
6LJ.F Valuation Measures
Enterprise Value | 36.33M EUR |
Trailing P/E | N/A |
Forward P/E | -3.9 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 23.547943 |
Price/Book (mrq) | 2.1869159 |
Enterprise Value/Revenue | 16.828 |
Enterprise Value/EBITDA | -1.582 |
Trading Information
Matinas BioPharma Holdings, Inc. Stock Price History
Beta (5Y Monthly) | 1.947 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 0.68 EUR |
52 Week Low | 0.1 EUR |
50-Day Moving Average | 0.18 EUR |
200-Day Moving Average | 0.32 EUR |
6LJ.F Share Statistics
Avg. Volume (3 month) | 2.45K EUR |
Avg. Daily Volume (10-Days) | 2.75K EUR |
Shares Outstanding | 217.26M |
Float | 210.48M |
Short Ratio | N/A |
% Held by Insiders | 2.91% |
% Held by Institutions | 12.16% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | September 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -1081.93% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -37.75% |
Return on Equity (ttm) | -68.84% |
Income Statement
Revenue (ttm) | 2.16M EUR |
Revenue Per Share (ttm) | 0.01 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -13490000 EUR |
EBITDA | -22967000 EUR |
Net Income Avi to Common (ttm) | -21262000 EUR |
Diluted EPS (ttm) | -0.09 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 18.22M EUR |
Total Cash Per Share (mrq) | 0.08 EUR |
Total Debt (mrq) | 3.71M EUR |
Total Debt/Equity (mrq) | 16.02 EUR |
Current Ratio (mrq) | 6.19 |
Book Value Per Share (mrq) | 0.107 |
Cash Flow Statement
Operating Cash Flow (ttm) | -14998000 EUR |
Levered Free Cash Flow (ttm) | -8260851 EUR |
Profile of Matinas BioPharma Holdings, Inc.
Country | Germany |
State | NJ |
City | Bedminster |
Address | 1545 Route 206 South |
ZIP | 07921 |
Phone | 908 484 8805 |
Website | https://www.matinasbiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 34 |
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Q&A For Matinas BioPharma Holdings, Inc. Stock
What is a current 6LJ.F stock price?
Matinas BioPharma Holdings, Inc. 6LJ.F stock price today per share is 0.17 EUR.
How to purchase Matinas BioPharma Holdings, Inc. stock?
You can buy 6LJ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Matinas BioPharma Holdings, Inc.?
The stock symbol or ticker of Matinas BioPharma Holdings, Inc. is 6LJ.F.
Which industry does the Matinas BioPharma Holdings, Inc. company belong to?
The Matinas BioPharma Holdings, Inc. industry is Biotechnology.
How many shares does Matinas BioPharma Holdings, Inc. have in circulation?
The max supply of Matinas BioPharma Holdings, Inc. shares is 287.97M.
What is Matinas BioPharma Holdings, Inc. Price to Earnings Ratio (PE Ratio)?
Matinas BioPharma Holdings, Inc. PE Ratio is now.
What was Matinas BioPharma Holdings, Inc. earnings per share over the trailing 12 months (TTM)?
Matinas BioPharma Holdings, Inc. EPS is -0.1 EUR over the trailing 12 months.
Which sector does the Matinas BioPharma Holdings, Inc. company belong to?
The Matinas BioPharma Holdings, Inc. sector is Healthcare.